Markets:

Overview

News

Currencies

International

Treasuries

Supernus Pharmaceuticals, Inc. - Common Stock (NQ:SUPN)

45.31 +0.20 (+0.44%)

Streaming Delayed Price Updated: 10:36 AM EDT, Aug 25, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Supernus Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

3 Stocks Under $50 We Steer Clear Of

October 20, 2025

The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to...

Via StockStory

SUPERNUS PHARMACEUTICALS INC (NASDAQ:SUPN) Presents a Compelling Mix of Growth and Technical Momentum ↗

October 17, 2025

Supernus Pharmaceuticals (SUPN) is a strong growth stock with a debt-free balance sheet and a positive technical breakout pattern. Explore its potential.

Via Chartmill

Branded Pharmaceuticals Stocks Q2 Earnings Review: Supernus Pharmaceuticals (NASDAQ:SUPN) Shines

October 12, 2025

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Supernus Pharmaceuticals (NASDAQ:SUPN)...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Supernus Pharmaceuticals (SUPN) Stock Is Up, What You Need To Know

October 09, 2025

Shares of specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) jumped 4.6% in the morning session after Piper Sandler upgraded the company's stock from a "Neutral" to an "Overweight"...

Via StockStory

Topics Artificial Intelligence

Crowdstrike To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Thursday ↗

October 09, 2025

Via Benzinga

Q2 Earnings Highs And Lows: Organon (NYSE:OGN) Vs The Rest Of The Branded Pharmaceuticals Stocks

October 08, 2025

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Organon (NYSE:OGN) and the best and worst...

Via StockStory

Topics Artificial Intelligence Intellectual Property

SUPERNUS PHARMACEUTICALS INC (NASDAQ:SUPN) Represents an Affordable Growth Opportunity ↗

October 07, 2025

Supernus Pharmaceuticals (SUPN) offers affordable growth with strong earnings, a clean balance sheet, and an attractive P/E ratio below industry peers.

Via Chartmill

Pharma ETFs In A Tariff Storm: How Investors Can Hedge Risk ↗

September 29, 2025

The U.S. pharmaceutical industry is at the center of a policy maelstrom.

Via Benzinga

Topics ETFs

Branded Pharmaceuticals Stocks Q2 Highlights: Collegium Pharmaceutical (NASDAQ:COLL)

September 24, 2025

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Collegium Pharmaceutical...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Biogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe

September 17, 2025

From Biogen Inc.

Via GlobeNewswire

3 Overrated Stocks with Questionable Fundamentals

September 08, 2025

Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements, or favorable market conditions.

Via StockStory

SUPERNUS PHARMACEUTICALS INC (NASDAQ:SUPN) Emerges as a Top Affordable Growth Stock ↗

September 08, 2025

SUPERNUS (SUPN) offers affordable growth with strong EPS & revenue expansion, solid profitability, and a sound financial base, all at a discount to the pharmaceutical industry.

Via Chartmill

Unpacking Q2 Earnings: Eli Lilly (NYSE:LLY) In The Context Of Other Branded Pharmaceuticals Stocks

September 07, 2025

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Eli Lilly (NYSE:LLY) and the best and worst...

Via StockStory

Topics Artificial Intelligence Intellectual Property

1 Cash-Producing Stock to Research Further and 2 We Brush Off

September 05, 2025

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

Via StockStory

Unpacking Q2 Earnings: Elanco (NYSE:ELAN) In The Context Of Other Pharmaceuticals Stocks

September 01, 2025

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Elanco (NYSE:ELAN) and the best and worst...

Via StockStory

Topics Artificial Intelligence Intellectual Property

2 Healthcare Stocks on Our Watchlist and 1 We Avoid

September 01, 2025

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Despite the rosy long-term prospects, short-term headwinds such as COVID...

Via StockStory

Topics Stocks

Spotting Winners: Pfizer (NYSE:PFE) And Branded Pharmaceuticals Stocks In Q2

August 27, 2025

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking at branded pharmaceuticals stocks, starting...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Supernus Pharmaceuticals to Participate in September Investor Conferences

August 27, 2025

From Supernus Pharmaceuticals, Inc.

Via GlobeNewswire

Branded Pharmaceuticals Stocks Q2 Recap: Benchmarking Bristol-Myers Squibb (NYSE:BMY)

August 26, 2025

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Bristol-Myers Squibb (NYSE:BMY) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

August 26, 2025

Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps...

Via StockStory

2 Safe-and-Steady Stocks to Target This Week and 1 We Brush Off

August 25, 2025

Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.

Via StockStory

Integer Holdings, Astrana Health, Surgery Partners, IQVIA, and Supernus Pharmaceuticals Shares Skyrocket, What You Need To Know

August 22, 2025

A number of stocks jumped in the afternoon session after the major indices rebounded, as Fed Chair Jerome Powell delivered dovish remarks at the much-awaited Jackson Hole symposium. Powell suggested...

Via StockStory

Topics Economy

1 Small-Cap Stock with Competitive Advantages and 2 We Brush Off

August 21, 2025

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a...

Via StockStory

Supernus Pharmaceuticals Inc (NASDAQ:SUPN) Fits the Affordable Growth Strategy with Strong Fundamentals and Attractive Valuation ↗

August 18, 2025

Supernus Pharmaceuticals (SUPN) offers strong growth, solid profitability, and fair valuations, making it an ideal pick for Affordable Growth investors.

Via Chartmill

Q2 Rundown: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Other Pharmaceuticals Stocks

August 17, 2025

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the pharmaceuticals industry, including Jazz Pharmaceuticals (NASDAQ:JAZZ) and its...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Winners And Losers Of Q2: Zoetis (NYSE:ZTS) Vs The Rest Of The Branded Pharmaceuticals Stocks

August 17, 2025

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how branded pharmaceuticals stocks fared in Q2, starting with...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Branded Pharmaceuticals Stocks Q2 In Review: Merck (NYSE:MRK) Vs Peers

August 14, 2025

Wrapping up Q2 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Merck (NYSE:MRK) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

Clover Health, Surgery Partners, Illumina, Bruker, and Supernus Pharmaceuticals Shares Skyrocket, What You Need To Know

August 13, 2025

A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer...

Via StockStory

Topics Economy

SUPN Q2 Deep Dive: Growth Drivers Shift to New Portfolio as Legacy Products Fade

August 12, 2025

Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported Q2 CY2025 results topping the market’s revenue expectations, but sales fell by 1.7% year on year to $165.5 million. The...

Via StockStory

1 Momentum Stock for Long-Term Investors and 2 Facing Challenges

August 11, 2025

The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to new product launches, positive news, or even a dedicated social media...

Via StockStory

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.